It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
Anticholinergics may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events compared with six‐food elimination diet (very low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).
It is very uncertain whether mepolizumab 2.5 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).
It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 2.5 mg/kg (very low certainty).
Cromolyn sodium showed no clear difference in withdrawals due to adverse events at 8 weeks compared with placebo (low certainty).
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
It is very uncertain whether esomeprazole changes withdrawals due to adverse events at 8 weeks compared with fluticasone (very low certainty).